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1. Introduction 
Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia in the clinical 
practice with prevalence of over 2,200,000 and 1,300,000 in the United States and Japan, 
respectively. The prevalence of AF is strongly age dependent; less than 1% of individuals 
aged <60 years, but approximately 5% of those older than 65 years and about 8% of those 
older than 80 years are affected by AF (Furberg et al., 1994; Kannel et al., 1998). AF is not 
lethal arrhythmia but associated with an increased long-term risk of stroke, heart failure, 
and all-cause mortality (Stewart et al., 2002). One of the most debilitating consequences of 
AF is the accompanying risk of stroke, which occurs in an estimated 60,000 patients with AF 
per year in the United States (Go et al., 2001). 
Antiarrhythmic drug therapy remains a cornerstone to restore and maintain sinus rhythm 
for patient both with paroxysmal and persistent AF. However, conventional drugs such as 
sodium channel blockers (class I antiarrhythmic drugs) and potassium channel blockers 
(class III antiarrhythmic drugs) have limited efficacy, especially in persistent AF patients. 
Clinical studies have shown that the potassium channel blockers can terminate AF in only 
30% of cases (Ellenbogen et al., 1996; Falk et al., 1997). Sodium channel blockers are more 
effective than potassium channel blockers, but a potent sodium channel blocker, pilsicainide 
demonstrated a modest efficacy in converting AF to sinus rhythm, with a conversion rate of 
45% within 90 min in patients with recent-onset AF compared with 8.6% on placebo and 
was ineffective in chronic AF (Okishige at al., 2006). In addition, these conventional drugs 
have severe problematic risks of ventricular proarrhythmia, such as torsade de pointes (TdP) 
through excessive delay of ventricular replarization (Waldo et al., 1996; Trop-Pederson et al., 
1999) and left ventricular contractile dysfunction. Thus, the development of new 
antiarrhythmic agents which have more effective and safer profile is highly desirable. These 
days, the pharmaceutical industry has focused on “atrial-specific antiarrhythmic drug” in 
the search for safer drugs to terminate or prevent AF (Wirth et al., 2003; Vos 2004; Goldstein 
& Stambler 2005).  
The acetylcholine-activated potassium channel (IKACh channel) is one of the most 
promising targets for atrial-specific antiarrhythmic agent, because the channel is more 
abundantly expressed in the atrial than ventricle myocytes (Krapivinsky et al., 1995). In 
this article, the pathophysiolosical roles of IKACh channel in AF are summarized. In 
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addition, the in vitro and in vivo profiles of IKACh blockers and the usefulness for AF 
treatment are also discussed. 
2. Pathophysiological role of IKACh channel in AF 
The cardiac IKACh is a ligand-gated inward rectifier potassium current. The cardiac IKACh 
channel is heterotetramer of two distinct homologous proteins encoded by GIRK1 and 
GIRK4 (Kubo et al., 1993; Krapivinsky et al., 1995). The current amplitude is small under 
basal condition, but it is activated by acetylcholine secreted from the vagal nerve or by 
adenosine through muscarinic M2 receptor or adenosine A1 receptor, respectively. Activated 
M2 receptor and A1 receptor stimulate IKACh via GǃǄ protein activation (Fig. 1). Vagal nerve 
activation, acetylcholine or adenosine treatment shortens atrial effective refractory period 
(ERP), increases atrial ERP dispersion and promotes AF (Kabell et al., 1994; Liu and Nattel 
1997), possibly through the IKACh activation. A report with GIRK4 knockout mice showed 
that the IKACh channel plays a crucial role in the initiation of AF (Kovoor et al., 2001). In 
addition, it is well known that the enhancement of vagal nerve tone can lead to paroxysmal 
AF in human (Chen et al., 1998). 
 
 
Fig. 1. The different mechanism of IKACh activation mechanism between paroxysmal AF and 
persistent AF 
Although the enhancement of IKACh could be responsible for the initiation of paroxysmal AF 
in human (Chen et al., 1998), the pathophysiological role of IKACh in patient with persistent 
AF remains unclear. Dobrev et al. (2001, 2002) showed that the activation of IKACh by 
muscarinic receptor stimulation is smaller in atria from AF patients compared to those in 
patients with sinus rhythm. The total acetylcholine-induced inward current in atrial 
myocytes from AF patients reported to be larger than those from patient with sinus rhythm. 
However, this increase was due to the increased density of the inward rectifier K+ current 
(IK1); the density of IKACh was rather decreased in AF patients than SR patients (Bosch et al., 
1999). In addition, reduced muscarinic receptor-related activation of IKACh could be 
explained by decreased expression of the channel subunits (Dobrev et al., 2001; Brundel et 
al., 2001a, 2001b). Therefore, it had been thought that the IKACh channel is down-regulated in 
atrium of persistent AF patients and the effects of the channel blockers might have less 
effective in persistent AF patients. 
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However, recent studies suggested that a constitutively active component of IKACh channel 
exists and it may be upregulated in persistent AF patients. Tertiapin, a selective IKACh 
blocking peptide, concentration-dependently blocked the whole cell IKACh in persistent AF 
patients with a higher potency than that in patient with paroxysmal AF or sinus rhythm 
(Dobrev et al., 2005). The report clearly showed that the basal inward rectifying potassium 
current was larger in persistent AF patients, although the muscarinic receptor-activated 
component of IKACh was larger in patients with sinus rhythm or paroxysmal AF. In addition, 
single channel analysis revealed the presence of constitutively active IKACh channels in 
persistent AF patients but not in patients with sinus rhythm or paroxysmal AF (Dobrev et 
al., 2005). Such a tertiapin-sensitive and constitutively active current component 
contributing to basal outward current was detected in canine left atria and pulmonary vein, 
and the component was upregulated in preparations from tachycardia-remodeled atria 
(Ehrlich et al., 2004). In addition, tertiapin prolonged the atrial action potential duration 
(APD) and prevented AF development in canine tachycardia-remodeled atria (Cha et al., 
2006). These results suggest that the receptor-independent IKACh is activated and plays a 
crucial role in persistent AF patients. 
The molecular mechanism underlying constitutive IKACh channel activation in remodeled 
atria remains unknown. The regulation of IKACh is complex and the channel activity is 
modulated by levels of intracellular Na+ concentration (Sui et al., 1996), ATP (Sui et al., 1996; 
Kim et al., 1997) phosphatidylinositol biphosphate (Huang et al., 1998), and fatty acid (Kim 
and Pleumsamran, 2000). Recently, Voigt et al. (2007) reported that abnormal PKC function 
might play important role in the occurrence of constitutive IKACh activation in clinical AF. 
Although further work will be needed to define the precise signaling mechanisms that 
enhance the channel activity, modified phosphorylation dependent channel regulation may 
contribute to the development of constitutive IKACh activity (Fig. 1).  
3. In vitro and in vivo profiles of selective IKACh blockers  
Several class III antiarrhythmic drugs have been shown to block IKACh in atrial cell 
(Guillemare et al., 2000; Mori et al., 1995). The blocking effects on IKACh might work 
additively for their antiarrhythmic efficacy. However, the effects of these drugs on IKACh are 
not so potent. In addition, the drugs block other cardiac potassium current, including the 
rapid rectifier potassium current, IKr. Thus, investigations using more potent and selective 
blocker are needed to clarify the therapeutic potential, atrial selectivity and safety of IKACh 
blockers. In this session, the pharmacological profiles of potent IKACh blockers, tertiapin, 
NIP-141 and NIP-151 are discussed.  
3.1 Pharmacological profile of tertiapin, a selective IKACh blocking peptide 
Tertiapin is a 21 amino acid residue peptide with two disulfide bonds, isolated from venom 
of the European honey bee. The peptide was shown to block IKACh potently in cardiac 
myocyte (Jin and Lu 1998). This peptide inhibits, in a concentration-dependent manner (IC50 
= ~8 nmol/L), acetylcholine or GTP analogue-induced whole cell current in rabbit atrial 
myocyte (Kitamura et al., 1994). For the information of selectivity of the peptide, Drici et al. 
(2000) reported that tertiapin selectively inhibited IKACh at IC50 of about 30 nmol/L without 
significant effects at 1 μmol/L on IK1, IKr, the transit owtward current (Ito), the ultra-rapid 
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delayed rectifier K+ current (IKur), the slow component of the delayed rectifier K+ current 
(IKs), fast sodium current (INa) and L-type calcium current (ICa). Tertiapin was the first 
reported selective IKACh blocker, so we used this peptide to clarify the pathophysiological 
role of IKACh in AF. 
 
 
Table 1. Efficacy of tertiapin in terminating vagal nerve stimulation (VNS)-induced atrial 
fibrillation (AF) and aconitine- induced AF in dogs (Hashimoto et al., 2006) 
 
 
Fig. 2. (A) Effects of tertiapine (12 nmol/kg; solid column) and vehicle (saline; blank 
column) on atrial and ventricular effective refractory period with vagal nerve stimulation in 
dogs. Data are expressed as mean ± S.E.M. (n=4) *P<0.05, *P<0.01 compared with vehicle 
treated group. (B) Effects of tertiapin (4-41 nmol/kg) on ECG parameters: PQ(■), QRS(▲) 
intervals and corrected QT value (QTc; ●) in anesthetized beagle dogs. Data are expressed as 
mean ± S.E.M. (n=4; Hashimoto et al., 2006). 
We examined the effects of tertiapin on the two canine AF models: vagal nerve stimulation 
(VNS)-induced and aconitine-induced AF models, to clarify the antiarrhythmic potential of 
IKACh blockade. VNS-induced model and aconitine-induced model have been known as 
different type of paroxysmal AF models; a micro-reentry type AF model and ectopic-focus 
induced AF model, respectively. Intravenous injection of tertiapin (4-41 nmol/kg) 
terminated AF in both canine AF models (Hashimoto et al., 2006, Table 1). Tertiapin (12 
nmol/kg) significantly prolonged atrial ERP at the basic cycle length of 200 and 300 ms 
without affecting conduction velocity in atria under VNS condition (Fig. 2A). The result 
suggests that AF termination by tertiapin is associated with atrial ERP prolongation. 
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Alternatively, tertiapin at the effective dose ranges (4-42 nmol/kg) had no significant effects 
on ECG parameters such as PQ, QRS and corrected QT (QTc) intervals and ventricular ERP 
in anesthetized dogs (Fig. 2B; Hashimoto et al., 2006). These results suggest that IKACh has a 
crucial role in the maintenance of paroxysmal AF, but has no contribution in ventricular 
repolarization.  
3.2 Pharmacological profile of NIP-142, a multiple channel blocker 
The studies using tertiapin clearly suggests that IKACh blocker is effective in some types of 
AF patients. AF is chronic cardiac disease and the patients have to take medicine for a long 
term. Thus, the orally active small molecule would be good for the AF treatment. Tertiapin 
is a peptide and cannot be applied for oral administration. Thus, we conducted the 
screening of the blocker and found a candidate compound. NIP-142, (3R*, 4S*)-4-
cyclopropylamino-3,4- dihydro-2,2-dimethyl-6-(4-methoxyphenylacetylamino)-7-nitro-2H-1-
benzopyran-3-ol is synthesized by Nissan Chemical Industries, LTD. (Tanaka & Hashimoto, 
2007). The compound has inhibitory effects on multiple potassium channels including IKACh 
(GIRK1/GIRK4) channel (Table 2). The bioavailability of NIP-142 is about 25-50% in rats 
and more than 75% in dogs (Tanaka & Hashimoto, 2007), which suggests that the compound 
would be orally active. 
 
Kv1.5 HEK293 4.8 µM Matsuda et al. 2001
Xenopus  oocyte 100 µM -
GIRK1/GIRK4 HEK293 0.64 µM Matsuda et al. 2006
Xenopus  oocyte 10 µM Matsuda et al. 2005
hERG HEK293 44 µM Matsuda et al. 2004
KCNQ1/KCNE1 HEK293 12 µM -
Kv4.3, Kv4.2 Xenopus  oocyte >100 µM -
effect of NIP-142 (IC50) referencechannel host cell
 
Table 2. Inhibitory effects of NIP-142 on membrane currents 
3.2.1 Effect of NIP-142 on the membrane currents 
Effects of NIP-142 on various outward membrane currents have been studied by voltage 
clamp analyses (Table 2). The delayed rectifier current has three components: the rapid 
component, IKr, the slow component, IKs and the ultrarapid component, IKur. The effects on 
IKr, IKs and IKur were examined with HEK293 cells expressing the human ether a-go-go 
(hERG) channel, the human KCNQ1/KCNE1 channel and human Kv 1.5 channel, 
respectively (Matsuda et al., 2001, 2006). NIP-142 concentration-dependently inhibited these 
three channel currents. The IC50 on IKr, IKs and IKur were 44, 12 and 4.8 μmol/L, respectively 
(Matsuda et al., 2001; 2006). NIP-142 also inhibited the mouse Kv4.2 and Kv4.3 currents but 
the potency was very low. This compound had a slight effect on IK1: about 40% inhibition 
was observed with 10 μmol/L NIP-142.  
The effect of NIP-142 on IKACh was examined in HEK293 cells (Matsuda et al., 2006) and 
Xenopus oocytes (Matsuda et al., 2005) expressing the GIRK1/GIRK4 channel. 
Concentration- dependent inhibition of the current was observed in both types of cells: the 
inhibitory effect was 8-10 times potent than those on IKur in both cells (Table 2). The 
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inhibition of GIRK1/GIRK4 current amplitude in HEK293 cells by 0.1, 1 and 10 μmol/L 
NIP-142 was 28.9 ± 5.3%, 58.4 ± 6.2% and 76.8 ± 8.4%, respectively (Matsuda et al., 2006). The 
inhibition was independent from the voltage dependency of the voltage clamp pulse. 
Among the repolarizing potassium channel currents, NIP-142 inhibited the primarily the 
GIRK1/GIRK4 channel current which is IKACh (Table 2).  
Among other ion currents, NIP-142 at 10 μmol/L inhibited the peak inward current by 
about 50% and 25% for the L-type and T-type voltage-dependent calcium current in isolated 
guinea pig ventricular myocytes, respectively. At the same concentration, NIP-142 had no 
effects on the hyperpolarization- activated inward current (If) in isolated rabbit sinoatrial 
node cells. 
3.2.2 Effects of NIP-142 on the refractory period and action potential of isolated 
myocardium 
Effects of NIP-142 on the refractory period were studied in isolated guinea pig atrial and 
ventricular preparations. At 10 and 100 μmol/L, NIP-142 concentration-dependently 
prolonged the refractory period in atrium but not in ventricle (Matsuda et al., 2005). The 
action potential was measured with standard glass microelectrode techniques. NIP-142 
concentration-dependently prolonged APD only in the atrium. No significant changes in 
other action potential parameters, such as resting membrane potential, action potential 
amplitude and maximum rate of rise (Vmax), were observed (Matsuda et al., 2005).  
The effects of NIP-142 on refractory period and action potential were different from those of 
conventional class III agents. An IKr blocker E-4031 prolonged APD both in the atrium and 
the ventricle. In contrast, NIP-142 showed atrial selective prolongation of APD. The 
prolongation was mimicked by a selective IKACh blocking peptide, tertiapin (Matsuda et al., 
2005). These data suggested that the prolongation by NIP-142 was due to the IKACh blockade. 
Stimulation of the muscarinic receptor in the mammalian atria leads to a shortening of APD 
through activation of IKACh. NIP-142 (100 μmol/L) completely reversed the carbachol-
induced shortening of APD in canine (Nagasawa et al., 2006) and guinea-pig (Matsuda et al., 
2006) atrium. Such reversal also observed when NIP-142 was applied after the APD was 
shortened by adenosine (Matsuda et al., 2006), which also activates IKACh independent of 
muscarinic receptor. 
One of the major problems with existing antiarrhythmic drugs through prolongation of 
refractory period and APD is “reverse use-dependency”, the effect of the drugs are 
weakened under high stimulation frequency. Such effect is observed both in vitro and in 
vivo and may explain the ineffectiveness of the drug in high frequency in atrial fibrillation 
(Nattel, 1999). In guinea-pig atrium, E-4031 at 1 μmol/L prolonged APD when it was 
applied at pacing frequency less than 1 Hz, but not at frequencies higher than 2 Hz. In 
contrast, NIP-142-induced prolongation of atrial APD was unaffected by stimulation 
frequency (Matsuda et al., 2005), suggesting that the APD prolonging effect of the drug may 
be maintained in atrial fibrillation. 
3.2.3 Effects of NIP-142 on AF models 
In animal studies, NIP-142 terminated AF in various types of AF models (Table 3). 
Injection of NIP-142 (3 mg/kg) terminated AF after increase in fibrillation cycle length 
and prevented reinitiation of AF in VNS-induced model. This compound terminated 
macroreentry type of atrial flutter induced after placement of an intercaval crush without 
www.intechopen.com
 
Acetylcholine-Activated Potassium Channel as a Novel Target for AF Treatment 
 
327 
affecting atrial flutter cycle length (Nagasawa et al., 1999). NIP-142 prolonged atrial ERP 
by about 10% without affecting intraatrial and interatrial conduction times in these 
models, which suggested that the antiarrhythmic effects were achieved by the atrial ERP 
prolongation. We reported NIP-141 (the hydrochloride salt form of NIP-142) at 10 mg/kg 
terminated AF in aconitine-induced AF model (Hashimoto et al., 2007). Although the 
mechanism of AF termination in this model remains unclear, the IKACh blocking effect 
would be mainly involved, because tertiapin was also effective in this model (Hashimoto 
et al., 2006).  
 
effective dose of NIP-142 reference
3 mg/kg Nagasawa et al., 1999
3 mg/kg Nagasawa et al., 1999
10 mg/kg Hashimoto et al., 2007
2.5 mg/kg/10 min + 2 mg/kg/hr Hashimoto et al., 2008
model
vagally-induced AF model
intercaval crush-induced AFL model
atrial rapid pacing model
aconitine-induced AF model
 
Table 3. Effects of NIP-142 in models of atrial fibrillation (AF) and flutter (AFL) 
The ERP prolongation by NIP-142 was greater in the presence of VNS than normal 
condition (Nagasawa et al., 1999). We also reported that this compound at 3 mg/kg 
prolonged atrial ERP by about 20 ms under VNS, but at doses up to 10 mg/kg it had no 
significant atrial ERP prolongation effect without VNS (Hashimoto et al., 2007). These 
findings suggest that the NIP-142-induced atrial ERP prolongation is due mainly to the 
inhibition of IKACh.  
3.2.4 Low proarrhythmic risk with NIP-142 
NIP-141 (1-10 mg/kg) produced no significant prolongation of ventricular ERP in the 
pentobarbital-anesthetized dogs (Hashimoto et al., 2007). NIP-142-induced prolongation of 
atrial ERP was greater than that of ventricular ERP in AF models (Nagasawa et al., 1999). 
Because ventricular ERP or QT prolongation is not suitable for drug-induced TdP (Thomsen 
et al., 2003, 2004), we also evaluated the proarrhythmic risk of NIP-142 using the  
methoxamine-sensitized rabbit model, known as Carlsson model (Carlsson et al., 1990). By 
intravenous infusion, NIP-142 (30 mg/kg over 30 min) induced no ventricular arrhythmia in 
eight rabbits. In contrast, an IKr blocker, clofilium (15 mg/kg over 30 min) induced TdP in six 
of eight rabbits. These results suggests that NIP-142 has little effects on ventricular 
repolarization and not likely to cause proarrhythmia. 
In conclusion, NIP-142 preferentially blocks IKACh and has atrial selective ERP prolonging 
effects and antiarrhythmic effects in some AF models. This compound appeared to be, 
therefore, a potential therapeutic agent for the treatment and prevention of AF with lower 
risk of causing ventricular proarrhythmia than conventional drugs. However, NIP-142 at 
effective dose in AF model significantly decreased blood pressure. Because tertiapin had no 
significant effects on blood pressure, it was caused by the effects on other target except 
IKACh. NIP-142 has some blocking effects on ICaL and INa (Hashimoto et al., 2007), so the effect 
on blood pressure might be due to the blockade of these channels. 
3.3 Pharmacological profile of NIP-151, a novel IKACh channel blocker 
We modified the chemical structure of NIP-142 and found a more potent and selective IKACh 
channel blocker, NIP-151. The compound showed good bioavailability in dogs and rats, 
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almost same as that of NIP-142. The pharmacological profiles of NIP-142 and NIP-151 are 
shown in Table 4. NIP-151 blocks IKACh 400 times more potently than NIP-142, but the effects 
on ICaL and INa were less and about 7 times more potent than those of NIP-142, respectively. 
As a result, NIP-151 had no significant effects on blood pressure at the dose (0.3 mg/kg) that 
the compound prolonged atrial ERP by 38 ms under VNS. In contrast, NIP-142 decreased 
blood pressure by about 40% at the dose (3 mg/kg) that the compound prolonged ERP by 
20 ms under VNS.  
 
IKACh INa ICaL Atrial ERP prolongation Blood pressure 
20 ms -38%
38 ms -5%
6.6 >100
Effects on anesthetized dogsEffects on ion channels (IC50; μmo/L)
Compound 
NIP-142
NIP-151
(0.3 mg/kg)
(3 mg/kg)
0.65 45 44
0.0016
 
Table 4. The pharmacological profile of NIP-142 and NIP-151 
3.3.1 Effects of NIP-151 on ion channels 
The effects of NIP-151 on IKACh and IKr were examined using HEK293 cells expressing 
human GIRK1/GIRK4 channel and hERG channel, respectively by voltage clamp analyses 
(Hashimoto et al., 2008). NIP-151 at 0.1-100 nmol/L concentration-dependently inhibited the 
GIRK1/GIRK4 channel current (Fig. 3): NIP-151 at 0.1, 1, 10 and 100 nmol/L inhibited the 
current at -120 mV by 13.7 ± 24.8%, 42.0 ± 12.2%, 73.1 ± 4.1% and 87.2 ± 1.5%, respectively. 
The IC50 value for the inhibition of GIRK1/GIRK4 channel current was 1.6 nmol/L. NIP-151 
at 1, 10 and 100 μmol/L inhibited the tail current of hERG-channel current on repolarization 
by 15.3 ± 1.5%, 23.9 ± 3.4% and 73.3 ± 2.4%, respectively. The IC50 value for the inhibition of 
hERG channel current was 57.6 μmol/L. In our preliminary experiments, this compound 
had little effects (less than 50% inhibition at 10 μmol/L) on other components of the 
delayed rectifier potassium currents, IKur and IKs. NIP-151 was extremely selective for 
GIRK1/GIRK4 channel current over other repolarizing currents. 
The mechanism of IKACh blockade by NIP-151 remains unclear. We evaluated the effects of 
NIP-151 on muscarinic M2 receptor and adenosine A1 receptor using radioligands binding 
assay. NIP-151 had slight inhibitory effects on radio ligand binding to these receptors, but 
the effect was much weaker than that on IKACh: the IC50 on M2 and A1 receptors were 57.1 
μmol/L and 89.9 μmol/L, respectively. In addition, NIP-151 blocked IKACh in HEK293 cells 
or xenopus oocyte expressing GIRK1/GIRK4 only (not coexpressing these receptors). These 
results suggest that NIP-151 directly blocked IKACh channel or inhibited the downstream 
signaling pathway of these receptors.  
We also evaluated the NIP-151 on the various types of GIRK channel subtypes. Cardiac-
type and brain-type brain type GIRK channels are composed of GIRK1/GIRK4 and 
GIRK1/GIRK2 heteromultimeric subunits, respectively. NIP-151 preferentially blocked 
GIRK1/ GIRK4 channel current over GIRK1/GIRK2 current. In contrast, tertiapin blocked 
both currents at almost same potency (Matsumoto et al., 2008). The pathophysiological 
role of GIRK1/GIRK2 channel remains unclear, but seizure activity has been reported in 
GIRK2 null mice (Siqnorini et al., 1997). Thus, GIRK1/GIRK2 blocker might induce some 
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Fig. 3. Effects of NIP-151 on GIRK1/GIRK4 and hERG channel currents. (A) Typical 
GIRK1/GIRK4-channel current in the absence (control) and presence of NIP-151 at 100 
nmol/L. (B) Concentration-response relationship for blockade by NIP-151 of the 
GIRK1/GIRK1 channel current at 120 mV (solid circle) and the tale current of hERG-channel 
current (solid square). Data are shown as mean ± SEM from three to five experiments 
(Hashimoto et al., 2008). 
adverse effects on neural activity, such as seizure. Thus, inhibitory effects on GIRK1/GIRK4 
channel current over GIRK1/GIRK2 current might be preferable profile for anti AF agents. 
3.3.2 Effects of NIP-151 on paroxysmal AF models 
We examined the effects of NIP-151 on canine paroxysmal AF models and atrial and 
ventricular ERP, and compared against those of a standard class III agent dofetilide (Roukoz 
& Saliba 2007), which is clinically used for the management of AF. NIP-151 (15-30 
μg/kg/min) converted AF to sinus rhythm in canine VNS- and aconitine-induced AF 
models (Table 5, Fig. 4). The compound at the same doses (15-75 μg/kg/min) prolonged 
atrial ERP significantly, thus the AF termination effects were associated with the atrial ERP 
prolongation (Hashimoto et al., 2008). In contrast, a selective IKr blocker dofetilide, which 
had little effects on GIRK1/GIRK4 channel current, represented significant ERP 
prolongation both in the atrium and ventricle, but it was not effective in the VNS-induced 
and aconitine-induced AF models (Table 5).  
The reason why dofetilide did not show positive effects on AF models would be mainly 
due to reverse use dependency. In our preliminary study, dofetilide (0.3 μg/kg) 
prolonged atrial ERP by 29 ± 7 ms at a basic cycle length of 300 ms, but had slight 
prolongation (5 ± 5 ms) at a basic cycle length of 200 ms. Nattel et al. (1998) also have 
shown that dofetilide had limited efficacy in VNS-induced AF model, because of reverse 
use dependent ERP prolongation, compared with azimilide, which increased atrial ERP in 
a frequency-independent manner. Alternatively, NIP-151 (0.3 mg/kg) significantly 
prolonged atrial ERP by 41± 7 ms and 27 ± 5 ms at basic cycle lengths of 300 and 200 ms, 
respectively. These results suggest that the reverse use dependency of NIP-151 is less 
significant than that of IKr blockers such as dofetilide and consequently effective under 
the AF (high frequent) condition.  
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Fig. 4. Representative examples of atrial fibrillation (AF) termination with NIP-151. 
Electrograms from right atrium (RA) and right ventricular free wall (RV) were recorded. (A) 
Termination of vagal nerve stimulation-induced AF with NIP-151 at 15 μg/kg/min. (B) 
Termination of aconitine-induced AF with NIP-151 at 100μg/kg. (Hashimoto et al., 2008) 
 
dose termination time to AF  AF dose termination time to AF
(µg/kg/min) of AF termination(s) reinduction (µg/kg) of AF termination(s)
vehicle - 1/10 98 1/1 - 0/5 -
5  4/5* 525 ± 25 3/4 10 0/5 -
15   5/5** 372 ± 38 1/5 30  4/5* 85 ± 23
100   5/5** 76 ± 15
3 1/4 793 1/1
10 0/4 - -
Time to AF termination data were expressed as mean ±SEM
**P<0.01, *P<0.05 vs vehicle-treated group
100
aconitine-induced AF model
NIP-151
0/4 -dofetilide
VNS-induced AF model
 
 
Table 5. Effects of NIP1-151 and dofetilide in terminating vagal nerve stimulation (VNS)-
induced and aconitine-induced atrial fibrillation (AF). (Hashimoto et al., 2008) 
We also evaluated the effects of NIP-151 in canine atrial flutter model with Y-shaped right 
atrial incision. Intravenous infusion of NIP-151 (75 μg/kg/min over 10 min) did not 
terminated atrial flutter in this model (0 of four dogs), although the compound slightly 
prolonged atrial flutter cycle length. This result suggests that the IKACh blocker might have 
weak efficacy on macro-reentry type atrial flutter. 
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3.3.3 Low proarrhythmic risk with NIP-151  
We found that NIP-151 had little effects on hemodynamic (blood pressure, left ventricular 
systolic pressure and maximum left ventricular developed pressure increased rate) and 
electrophysiological values (PQ, QRs, QT and corrected QT) in isoflurane-anesthetized dogs, 
even when the drug was administrated at doses that 20- to 60- fold higher than the effective 
dose in the VNS-AF model. NIP-151 also represented no changes in action potential 
parameters (Vmax and APD) in beagle dog ventricular muscle, and no proarrhythmic effects 
in the methoxamine-sensitized rabbit model (Carlsson model). In contrast, dofetilide 
prolonged the QTc interval in anesthetized dogs and APD in beagle dog ventricular muscle, 
and it induced TdP in Carlsson model (Hashimoto et al., 2008). These results suggest that 
NIP-151 is expected to be devoid of a ventricular proarrhythmic effects rather than a 
clinically available class III drug. 
3.4 The effect of IKACh blockers in remodeled heart 
It is clinically observed that the recurrent episode of paroxysmal AF often progresses 
more persistent forms of AF. Wijffels et al. (1995) reported this phenomenon as “AF 
begets AF”. They found continuous rapid atrial pacing in the goat heart lead to progress 
shortening of atrial ERP and increased duration of AF once it is induced. This 
phenomenon was found to be associated with structural and electrical remodeling. 
Structural remodeling, characterized by fibrosis and hypertrophy, affects excitation 
pattern of atria and creates a substitute for AF development and maintenance (Ehrlich et 
al., 2006). Electric remodeling is accompanied by alterations in the expression and/or 
function of various ion channels in a way that promotes rapid and irregular activation of 
atria (Wijffels et al., 1995; Nattel et al., 2007). The ion channels affected by electrical 
remodeling include INa and IKr, which are targets of conventional antiarrhthmic agents. 
The expressions and activities of these channels are significantly decreased after atrial 
tachypacing, thus the conventional drugs have limited efficacies in the remodeled hearts 
of persistent AF patients. Thus, the development of a new drug which is effective in 
persistent AF patients is highly desirable. 
We evaluated the IKACh blockers on the canine atrial tachypacing model to predict the 
efficacy in persistent AF patients. The atrial tachypacing model was established by 7-10 days 
right atrial pacing at 400 bpm. In this model, the atrial ERP was significantly decreased by 
about 40 ms at a basic cycle length of 300 ms. Intravenous administration of NIP-151 (0.3 
mg/kg) prolonged atrial ERP by 15 ± 2 ms and 44 ± 8 ms at a basic cycle length of 300 ms 
before and after the atrial tachypacing, respectively. Tertiapin (12 nmol/kg) also prolonged 
atrial ERP by 7 ± 1 ms and 20 ± 1 ms at a basic cycle length of 300 ms before and after the 
atrial tachypacing, respectively (Fig. 5). The atrial ERP prolonging effects by these IKACh 
blockers was significantly potentiated after the atrial tachypacing. Interestingly, the atrial 
ERP prolongation by these IKACh blockers did not significant show use-dependency. The 
atrial ERP prolongations by NIP-151 (0.3 mg/kg) after the atrial tachypacing were 40 ± 6 ms, 
44 ± 8 ms and 32 ± 5 ms at basic cycle length of 400 ms, 300 ms and 200 ms. A selective IKr 
blocker, E-4031 prolonged atrial ERP before and after atrial tachypacing, but the prolonging 
effect was significantly decreased from 46 ± 7 ms to 25 ± 5 ms after atrial tachypacing  
(Fig. 5). These results suggest that IKACh blockers might have better efficacy in persistent AF 
patients than conventional IKr blockers.  
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Fig. 5. Effects of NIP-151, tertiapin and E-4031 on atrial effective refractory period (ERP) 
prolongation in atrial tachypacing model. The ERP was mesuared at the basic sysle length of 
300 ms. Data are shown as mean ± s.e.m. (n=4-5). **P<0.01 compared with before 
tachypacing. 
To clarify the activation mechanism of IKACh in this model, we evaluated the effects of a 
muscarinic M2 receptor antagonist, AF-DX116 and an adenosine A1 receptor antagonist, 
DPCPX. AF-DX 116 (0.3 mg/kg) slightly prolonged atrial ERP (~10 ms) before and after 
atrial tachypacing, but the prolonging effect was unchanged between before and after the 
pacing. DPCPX (0.3 mg/kg) had little effects on atrial ERP both before and after the atrial 
tachypacing. These results suggest the IKACh activation in the model would be associated 
with non-receptor regulated mechanism. As discussed above, constitutively IKACh is 
activated in the persistant AF patients and dogs with atrial tachypacing (Dobrev et al., 2005, 
Ehrlich et al., 2004). The potentiated ERP prolongation by NIP-151 and tertiapin after the 
atrial tachypacing might be associated with the blockade of constitutively active IKACh 
channel. 
4. Clinical implication  
Currently available anti-arrhythmic agents such as sodium channel blockers and potassium 
channel blockers have not only limited efficacy but also severe side effects such as 
proarrhythmia and reduced cardiac function (Li et al., 2009). Considerable attention has 
recently focused on atrial-selective AF drug. IKACh channel has been thought to be a good 
target for AF treatment, because the channel is important for atrial, but not for ventricular 
repolarization and AF susceptibility (Nattel & Carlsson, 2006). Paroxysmal AF occurring at 
night, at rest, and/or consuming meals or alcohol is caused at least partly by the activation 
of ligand-operated IKACh channel (Coumel, 1999). In addition, our results from atrial 
tachypacing model suggested that electrical remodeling increased the density of 
constitutively active IKACh that is activatedd in atrial cells through muscarinic receptor or 
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adenosine receptor-independent mechanism. The constitutively active IKACh channel is 
observed in cardiomyocytes from patients with persistent AF (Dobrev et al., 2005). These 
observations suggest that IKACh blockers would be effective not only in paroxysmal AF but 
also persistent AF treatment.  
Agonist-activated inward rectifier potassium current are lager in left than right atria of 
patients with paroxysmal AF (Voigt et al., 2010). The left-to-right gradient in inward rectifier 
background current may contribute to the left-to-right atrium dominant frequency gradients 
in paroxysmal AF patients, accelerating frequency and stability of reentry-promoting rotors. 
IKACh blockers might modify not only atrial refractoriness but also AF –promoting reentrant 
sources in the experimental models described. 
The contribution of IKACh channel activation to the development and maintenance of AF in 
patients remains unknown, because a highly selective IKACh blocker has not been clinically 
available. As with all animal experiments or human tissue studies, it might be difficult to 
predict whether the efficacy can be directly extrapolated to patients because the AF is 
complex and has varied manifestations. From this perspective, the clinical assessment to 
verify the importance of IKACh channel and to ascertain the therapeutic utility of a selective 
IKACh blocker is required.  
We have shown that the highly safe profile of IKACh blocker in cardiovascular systems, but 
there is little information about the adverse effects of the blockers on extracardiac organs. 
GIRK1/GIRK4 channel is mainly located in atrium, but other subtypes such as 
GIRK1/GIRK2, GIRK1/GIRK3, and GIRK2/GIRK3 are located in some types of neurons 
(Saenz del Burgo et al., 2008). The physiological roles of these subtypes have not been 
cleared, but seizure activity has been reported in GIRK2 null mice (Siqnorini et al., 1997). 
Before conducting clinical study, we have to examine fully the extracardiac effects of IKACh 
blockers.  
5. Conclusion  
Recent studies clearly showed that IKACh channel has a crucial role in the development and 
maintenance of AF. This channel would be a novel target for the treatment both in 
paroxysmal and persistent AF patients. IKACh blockers terminated AF in some canine AF 
models with atrial-specific ERP prolongation. This profile is thought to be ideal for anti-AF 
agent, because the blockers have minimum risk of ventricular proarrhthmia such as TdP. 
Some drug candidates that block IKACh are under clinical or preclinical stages (Machida et al., 
2011; Ehrlich & Nattel, 2009; Voigt et al, 2009). The clinical efficiency of the blockers will be 
clarified in the near future.  
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